Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Top Cited Papers
Open Access
- 25 June 2015
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 125 (26), 3996-4009
- https://doi.org/10.1182/blood-2015-03-580027
Abstract
Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treatment of virtually all childhood acute lymphoblastiKeywords
This publication has 118 references indexed in Scilit:
- Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemiaBlood Cancer Journal, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemiaBlood, 2012
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesLeukemia, 2012
- Improved Prognosis for Older Adolescents With Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2011
- Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotypingLeukemia, 2010
- Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cellsBlood, 2009
- Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2009
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008